NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Want to cut your energy bills? Here’s how five experts are doing it 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
LA JOLLA, Calif., Feb. 27, 2017 -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced an oral presentation for its lead product candidate, tipifarnib, at the 15th International Congress on Targeted Anticancer Therapies (TAT 2017), taking place March 6-8, 2017 in Paris, France. The presentation will feature clinical data from the first stage of Kura Oncology’s tipifarnib Phase 2 program in HRAS mutant tumors.
Presentation:
Date & Time: March 6, 2017, 2:45 p.m. - 3:00 p.m. CET
Title of Presentation: Preliminary evidence of clinical activity with tipifarnib in squamous cell carcinomas of the head & neck (SCCHN) with HRAS mutations
Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Session: Plenary Session 3: Phase 1 Studies - Completed or in progress (miscellaneous drugs & targets)
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The pipeline includes KO-947, an ERK inhibitor, and KO-539, an inhibitor of the menin-MLL protein-protein interactions. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] MEDIA CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
